Journal article
Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort
AIDS (London), v 27(2)
14 Jan 2013
PMID: 23032418
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective: To understand the HIV-hepatitis B virus (HBV) epidemic from a global perspective by clinically and virologically characterizing these viruses at the time of antiretroviral therapy (ART) initiation in a multinational cohort.
Methods and design: HIV-infected patients enrolled in two international studies were classified as HIV-HBV coinfected or HIV monoinfected prior to ART. HIV-HBV coinfected patients were tested for HBV characteristics, hepatitis D virus (HDV), a novel noninvasive marker of liver disease, and drug-resistant HBV. Comparisons between discrete covariates used chi(2) or Fisher's exact tests (and Jonchkheere-Terpstra for trend tests), whereas continuous covariates were compared using Wilcoxon Rank-Sum Test.
Results: Of the 2105 HIV-infected patients from 11 countries, the median age was 34 years and 63% were black. The 115 HIV-HBV coinfected patients had significantly higher alanine aminotransferase and aspartate aminotransferase values, lower BMI, and lower CD4(+) T-cell counts than HIV monoinfected patients (median 159 and 137 cells/mu l, respectively, P = 0.04). In the coinfected patients, 49.6% had HBeAg-negative HBV, 60.2% had genotype A HBV, and 13% were HDV positive. Of the HBeAg-negative patients, 66% had HBV DNA 2000 IU/ml or less compared to 5.2% of the HBeAg-positive individuals. Drug-resistant HBV was not detected.
Conclusion: Screening for HBV in HIV-infected patients in resource-limited settings is important because it is associated with lower CD4(+) T-cell counts. In settings in which HBV DNA is not available, HBeAg may be useful to assess the need for HBV treatment. Screening for drug-resistant HBV is not needed prior to starting ART in settings in which this study was conducted. (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:191- 201
Metrics
Details
- Title
- Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort
- Creators
- Chloe L. Thio - Johns Hopkins UniversityLaura Smeaton - Harvard UniversityMelissa Saulynas - Johns Hopkins UniversityHyon Hwang - Johns Hopkins UniversityShanmugam Saravan - University of MadrasSmita Kulkarni - National AIDS Research InstituteJames Hakim - University of ZimbabweMulinda Nyirenda - University of MalawiHussain S. Iqbal - University of MadrasUmesh G. Lalloo - University of KwaZulu-NatalAnand S. Mehta - Drexel UniversityKimberly Hollabaugh - Harvard UniversityThomas B. Campbell - University of DenverShahin Lockman - Harvard UniversityJudith S. Currier - Supreme Council Of Health
- Publication Details
- AIDS (London), v 27(2)
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 11
- Grant note
- 1U01AI069456-01 / Gaborone Prevention/Treatment Trials CRS CTU 1U01AI069471-01 / Cook County Hospital CORE Center CTU AI069471 / Northwestern University CRS CTU 1U01AI069417-01 / NARI Pune CRS CTU U01AI069511-02; CRC:UL1RR 024160 / University of Rochester CTU AI25868 / Wake County Health and Human Services Clinical Research Site CTU National Institute of Mental Health (NIMH); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH) AI-069513 / University of Cincinnati CTU AI32782 / University of Texas, Galveston AI069423; RR 025747; AI050410 / UNC AIDS CRS CTU AI 046376 / University of Texas Southwestern Medical Center 1U01AI069417-01 / NARI Clinic at Gadikhana Dr Kotnis Municipal Disp CTU AI069428 / University of Southern California CRS CTU 1U01AI069518-01 / Kalingalinga Clinic CRS CTU AI46381 / SSTAR, Family Healthcare Center 1U01AI069518-01 / College of Med. JHU CRS CTU 1U01AI069470 / HIV Prevention & Treatment CRS CTU 1U01AI069476-01 / Instituto de Pesquisa Clinica Evandro Chagas CRS CTU Al-27665; Al069532 / New York University/NYC HHC at Bellevue Hospital CTU U01-AI069439 / Vanderbilt Therapeutics CRS CTU U01AI069419 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) 1U01AI069426-01 / Durban Adult HIV CRS CTU AI46370 / Beth Israel Med. Ctr., ACTU CTU U01-A1 069424 / Harbor-UCLA Medical Center CTU R01 AI071820; K24 AI56933; AI068636; AI69450; U01 AI068634; R01CA120206; R01CA136607 / National Institute of Allergy and Infectious Diseases at the National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) AI069419; RR024996 / Todd Stroberg, R.N., and Christina Megill, PA-C.-Cornell CTU CTU 1U01AI069432-01 / YRGCARE Medical Ctr., VHS CRS CTU 1U01AI069424-01 / UCLA CARE Center CRS CTU 1U01AI069401-01 / Hospital Nossa Senhora da Conceicao CRS CTU 1U01AI069417-01 / NARI Clinic at NIV CRS CTU R01CA120206 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) 1U01AI069399-01 / Chiang Mai Univ. ACTG CRS CTU 1U01AI069421-01 / Les Centres GHESKIO CRS CTU 1U01AI069463-01 / Wits HIV CRS CTU AI38858-09S1 / Univ. of California Davis Med. Ctr., ACTU U01-AI-AI69467-05 / Hospital of the University of Pennsylvania CRS CTU AI34853 / University of Hawaii at Manoa, Leahi Hospital AI69450 / University of Colorado Hospital CRS CTU AI27661 / University of Minnesota CTU 1U01AI069456-01 / Molepolole Prevention/Treatment Trials CRS CTU 5U01AI069438 / San Miguel CRS CTU 1U01AI069471-01 / Rush Univ. Med. Ctr. ACTG CRS CTU 1U01AI069495 / Washington U CRS CTU P30-AI-045008-12 / CFAR 1U01AI069436-01 / UZ-Parirenyatwa CRS CTU U01AI068636 / National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) U01AI069511-02; CTSI: UL1 RR 024160 / Christine Hurley, RN and Roberto Corales, DO-AIDS Care CRS CTU UL1RR025747 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) UL1TR000457 / NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) IAA Y1-AI-8374-01 / AMPATH at MOI Univ. Teaching Hosp. Eldoret CRS CTU 1U01AI069518-01 / University of North Carolina Project, Kamuzu Central Hospital CTU AI069484-06 / Duke University Medical Center CRS CTU National Institute of Dental and Craniofacial Research (NIDCR); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR) AI069472-01 / Miriam Hospital CTU AI069474 / Ohio State University CTU 5U01 AI069438 / Asociacion Civil Impacta Salud y Educacion, Sede Barranco CTU 1U01AI069456-01 / CTU Walter Reed Project - Kenya Med. Research Institute CTU
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000312542900007
- Scopus ID
- 2-s2.0-84872380490
- Other Identifier
- 991019319093804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Virology